DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/rddx98/company_study_of_w) has announced the addition of the "Company Study of Walvax Biotechnology Co, Ltd.,2012" company profile to their offering.

Walvax Biotechnology Co, Ltd., founded in 2001, specializes in research & development, production and marketing of bio-pharmaceutical vaccines. In September 2010, it went public on the Shenzhen's Growth Enterprise Market (GEM), with the approval of China Securities Regulatory Commission (CSRC). Walvax Biotechnology employs about 863 people, including 161 for research and development. It has a new-type vaccine research & development center and pilot base at Kunming High-tech Industrial Development Zone (located in Kunming, Yunnan province) as well as vaccine production bases at Yuxi Hi-Tech & New Industrial Development Zone (located in Yuxi, Yunnan province) and Taizhou National Medical Hi-Tech Development Zone (located in Taizhou, Jiangsu province). In addition, its marketing network covers 30 provinces or cities and more than 2000 regions or counties throughout China

Key Topics Covered:

1 Profile

2 Operation

3 Revenue Structure

4 Gross Margin

5 Client and Supplier

6 R&D and Investment

See the article here:
Research and Markets: Company Study of Walvax Biotechnology Co, Ltd.,2012